Macrophage colony-stimulating factor (M-CSF) prevents infectious death induced by chemotherapy in mice, while granulocyte-CSF does not

Japanese Journal of Cancer Research

Volumn 93, Issue 4, 2002, Pages 426-435

  Hidaka, Takao ^a   Fujimura, Masaki ^a   Nakashima, Akitoshi ^a   Higuma, Subaru ^a   Yamagishi, Naoko ^a   Tsuda, Hiroshi ^a   Sakai, Masatoshi ^a   Saito, Shigeru ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Chemotherapy; G CSF; Granulocyte function; Infection; M CSF

Indexed keywords

ANION; CD11B ANTIGEN; CD18 ANTIGEN; CELL ADHESION MOLECULE; CISPLATIN; CYCLOPHOSPHAMIDE; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MITOMYCIN; RECOMBINANT COLONY STIMULATING FACTOR 1; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BLOOD CULTURE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL COUNT; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG INDUCED DISEASE; GRANULOCYTE; GRANULOCYTE FUNCTION; INFECTION PREVENTION; INFECTIOUS COMPLICATION; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SEPSIS; SURVIVAL RATE; THROMBOCYTE COUNT;

EID: 0036244479     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb01274.x     Document Type: Article

References (47)

1. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma
2. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation
3. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
4. Lenograstim: An update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings
5. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: Out-patient treatment is a viable option
6. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer
7. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose refractory and relapsed acute myeloid leukemia
8. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
9. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial
10. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Research Council Multicenter Randomized Trial
11. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose refractory and relapsed acute myeloid leukemia
12. High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia
13. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration
14. Purification and some properties of colony-stimulating factor from human urine
15. The macrophage colony-stimulating factor, CSF-1
16. Granulopoietic and thrombopoietic activity of human macrophage colony-stimulating factor
17. In vivo effects of macrophage colony-stimulating factor on human monocyte function
18. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to leukemia, a double-blind controlled study
19. A double-blind controlled study of urinary M-CSF after chemotherapy for ovarian cancer: Clinical usefulness
20. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia
21. Macrophage colony-stimulating factor prevents febrile neutropenia induced by chemotherapy
22. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy
23. In vivo activation of human neutrophil functions by administration of recombinant human granulocyte colony-stimulating factor in patients with malignant lymphoma
24. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients
25. Neutrophil kinetics shortly after initial administration of recombinant human granulocyte colony-stimulating factor: Neutrophil alkaline phosphatase activity as an endogeneous marker
26. Differential effects of granulocyte- and granulocyte-macrophage colony-stimulating factors (G- and GM-CSF) on neutrophil adhesion in vitro and in vivo
27. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstin in small-cell lung cancer
28. Granulocyte colony-stimulating factor in severe chemotherapy induced afebrile neutropenia
29. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: Results of a prospective randomized trial
30. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL)
31. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma
32. Granulocyte-colony stimulating factor for the prevention of chemotherapy-induced febrile neutropenia in the adult cancer patient population of Southern Israel
33. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: No significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B
34. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: An analysis using a Markov model
35. Enhanced antitumor effect of recombinant human tumor necrosis factor in combination with recombinant human granulocyte colony-stimulating factor in BALB/c mice
36. Induction of tumor necrosis factor in mice by recombinant human macrophage colony-stimulating factor
37. Flow cytometric identification of murine neutrophils and monocytes
38. Analysis of neoplasms induced by Cas-Br-M MuLV tumor extracts
39. Demonstration of functionally distinct human polymorphonuclear leukocyte fractions by simultaneous measurement of phagocytosis and oxygen radical generation
40. A fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine 123
41. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation
42. Leukocyte-endothelial adhesion molecules
43. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia
44. Restored chemotherapy-induced granulocyte dysfunction by macrophage colony-stimulating factor via secondary IL-8 production by monocytes
45. Neutrophil-activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils
46. Macrophage colony-stimulating factor induces interleukin-8 production in human monocytes
47. In vivo stimulatory effect of macrophage colony-stimulating factor on the number of stroma-initiating cells